Search Results - "Burgers, J.A"

Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England by Damhuis, R.A, Khakwani, A, De Schutter, H, Rich, A.L, Burgers, J.A, van Meerbeeck, J.P

“…Highlights • Currently, more than half of mesothelioma patients are 70 years or older. • Chemotherapy use for mesothelioma varies between countries. • Survival…”
Get full text

A Randomized Controlled Trial comparing Indwelling Pleural Catheters with Talc Pleurodesis (NVALT-14) by Boshuizen, R.C, vd Noort, V, Burgers, J.A, Herder, G.J.M, Hashemi, S.M.S, Hiltermann, T.J.N, Kunst, P.W, Stigt, J.A, van den Heuvel, M.M

“…Highlights • Indwelling pleural catheter and talc pleurodesis are both effective treatments for recurrent malignant pleural effusion. • No difference was…”
Get full text

OC-0578: Mediastinal lymph node position variability in relation to the carina in radical irradiated lung cancer patients by Schaake, E.E, Rossi, M.M.G, Buikhuisen, W.A, Belderbos, J.S.A, Burgers, J.A, Sonke, J.J

Get full text

PO-0680: The effect of metformin on radiotherapy outcome in non small cell lung cancer patients treated with chemoradiation by Rossi, M.M.G, Uyterlinde, W, Peulen, H.M.U, Knegjens, J.L, Diessen, J.N.A, Burgers, J.A, Dielemans, E, Troost, E, Sonke, J.J, Belderbos, J.S.A

Get full text

Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum–gemcitabine chemotherapy by Joerger, M, deJong, D, Burylo, A, Burgers, J.A, Baas, P, Huitema, A.D.R, Beijnen, J.H, Schellens, J.H.M

“…Abstract Background The aim of this study was to assess the predictive value of tumor expression of nine genes on clinical outcome in patients with advanced…”
Get full text

9112 POSTER AVAPERL1 (MO22089) – Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx) by Ahn, M, Gervais, R, Mezger, J, Reck, M, Orlov, S, Burgers, J.A, Bearz, A, Grossi, F, Lutiger, B, Barlesi, F

Get full text

Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients by Kappers, I, Belderbos, J.S.A, Burgers, J.A, van Zandwijk, N, Groen, H.J.M, Klomp, H.M

“…Summary The combination of radiotherapy and concurrent chemotherapy followed by surgery (trimodality treatment) is currently regarded as optimal treatment for…”
Get full text

A less severe phenotype in ovulatory women with polycystic ovary syndrome (PCOS) by Burgers, J.A, Lie Fong, S, Louwers, Y.V, Valkenburg, O, Laven, J.S.E

Get full text

Mapping Use of Radiotherapy for Patients with Non-small Cell Lung Cancer in the Netherlands between 1997 and 2008 by Koning, C.C.E, Aarts, M.J, Struikmans, H, Poortmans, P.M.P, Lybeert, M.L.M, Jobsen, J.J, Coebergh, J.W.W, Janssen-Heijnen, M.L.G, Visser, O, Louwman, W.J, Burgers, J.A

“…Abstract Aim After the publication of several reports that the utilisation rate of radiotherapy for patients with non-small cell lung cancer (NSCLC) varies for…”
Get full text

6575 POSTER Is there still a place for surgery in the treatment of locally-advanced non-small cell lung cancer (IIIA, N2)? by Klomp, H.M, Kappers, I, Burgers, J.A, van Zandwijk, N

Get full text

O.5.2 - Characteristics of Patients with Advanced Cancer Preferring Not to Know Prognosis: Presenter(s): Inge Henselmans, Amsterdam University Medical Centers, Netherlands by van der Velden, N.C.A., van Laarhoven, H.W.M., Burgers, J.A., Hendriks, L.E.L., De Vos, F.Y.F.L., Dingemans, A.M.C., van Haarst, J.M.W., Dits, J., Smets, E.M.A.

“…For some patients with advanced cancer not knowing prognosis is essential. Yet, in an era of informed decision-making, the potential protective function of…”
Get full text

Characteristics of Patients with Advanced Cancer Preferring Not to Know Prognosis by van der Velden, N.C.A., van Laarhoven, H.W.M., Burgers, J.A., Hendriks, L.E.L., De Vos, F.Y.F.L., Dingemans, A.M.C., van Haarst, J.M.W., Dits, J., Smets, E.M.A.

Get full text

6566 POSTER Surgical resection for Pancoast tumours after neoadjuvant chemoradiotherapy? by Kappers, I, Belderbos, J.S.A, Burgers, J.A, van Sandick, J.W, van Zandwijk, N, Klomp, H.M

Get full text

8166 POSTER Permanent Pleurx catheters for recurrent malignant pleural effusion by Olijve, A, Burgers, J.A, Buikhuizen, W, Baas, P, Zandwijk, N, Heuvel, M

Get full text

Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma by Dumoulin, D W, Douma, L H, Hofman, M M, van der Noort, V, Cornelissen, R, de Gooijer, C J, Burgers, J A, Aerts, J G J V

“…Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab…”
Get full text

Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort by van der Wel, J.W.T., Jebbink, M., van den Broek, D., Steinbusch, L.C., Theelen, W.S.M.E., Ruiter, G., Buikhuisen, W., Burgers, J.A., Baas, P., Vermeulen, M., van der Noort, V., Hashemi, S.M.S., Bosch, L.J.W., Monkhorst, K., Smit, E.F., Boelens, M.C., de Langen, A.J.

“…•Additional value in synchronous resistance mechanism analysis in tumor and plasma samples from patients developing disease progression due to osimertinib…”
Get full text

Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis by van Turenhout, Sietze T, Berghuis, Marieke, Snaebjornsson, Petur, Wilgenhof, Sofie, Burgers, J A, Haanen, John B A G, van Dieren, Jolanda M

Get more information

Ultra-sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine in human plasma for a microdose clinical trial by van Nuland, M., Hillebrand, M.J.X., Rosing, H., Burgers, J.A., Schellens, J.H.M., Beijnen, J.H.

“…•Ultra-sensitive method to quantify gemcitabine and dFdU.•Limit of detection of 2.5 pg/mL for gemcitabine and 250 pg/mL for dFdU.•Simple sample pretreatment…”
Get full text

A randomized phase II study comparing paclitaxel–carboplatin–bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170) by Dingemans, A.-M. C., Groen, H.J.M., Herder, G.J.M., Stigt, J.A., Smit, E.F., Bahce, I., Burgers, J.A., van den Borne, B.E.E.M., Biesma, B., Vincent, A., van der Noort, V., Aerts, J.G.

“…Nitroglycerin (NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia-inducible-factor (HIF)-1. A randomized phase II study has shown improved…”
Get full text

Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose by Van Nuland, M., Rosing, H., Thijssen, B., Burgers, J.A., Huitema, A.D.R., Marchetti, S., Schellens, J.H.M., Beijnen, J.H.

“…Microdose studies are exploratory trials to determine early drug pharmacokinetics in humans. In this trial we examined whether the pharmacokinetics of…”
Get full text